Product Datasheet

 
Product Description
 
Product: Immobilized RBD of SARS-CoV-2 Spike Protein
Catalog Number: RBD-I
Product Page: https://www.mol-innov.com/products/ICOV2RBDRHISIMM100UL
Description: SARS-CoV-2 is the novel coronavirus that causes CoronaVirus Disease 2019 (COVID-19). The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein binds to the cell receptor ACE2 allowing viral entry and infection. It is a 223 amino acid glycoprotein representing residues 319-541 of the spike protein S1 sequence. Immobilized RBD from Molecular Innovations is useful for capturing SARS-CoV-2 specific antibodies from human plasma and serum. Immobilized RBD of SARS-CoV-2 Spike Protein is highly specific and reusable. Recombinantly produced in HEK cell culture and purified by chelated metal affinity chromatography. Contains a 6X-Histidine tag at C terminus for purification.
Produced under license from the Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Recommended Storage: SAMPLE
Minimum Shelf Life: 486.50
Source: 1.0 mg/ml coupled
Molecular Weight: Proteins
Extinction Coefficient: 25,900
Antigen: 4 C
Target: Resin
Target Molecular Weight: COVID-19
Host: 4196.5
Clonality: 30
Isotype: Human Embryonic Kidney cells
Clone: s
Applications: Cold pack
Cross-reactivity: 12 months from delivery
 
Sample Characteristics
 
Lot Number: RBD-I-ICOV2RBDRHISIMM1ML
Aliquot: 1 x SARS-CoV-2 Spike Protein RBD Recombinant HIS Labeled Immobilized 1ml
Concentration: 695
Volume: 5995
Specific activity: SodiumAzide
Titer: PBS; 0.1% Sodium Azide
Buffer: SAMPLE
Form: 0.1 ml
Preservative: 0.2 ml of 1:1 slurry
 
Optimal experimental conditions and working dilutions must be determined by the end user. Sample concentration and volume are for example purposes only and do not necessarily represent the product that will be received. Please contact us for a current lot-specific product datasheet.
 
For in vitro laboratory use only
 
Molecular Innovations, Inc. - 46430 Peary Court, Novi, MI 48377, USA
Tel: (888) 557-5055 - Fax: (248) 896-0148 - info@mol-innov.com